Pharsight

Genzyme Corp patents expiration

1. Caprelsa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE42353 GENZYME CORP Quinazoline derivatives and pharmaceutical compositions containing them
Jun, 2022

(1 year, 9 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642608 GENZYME CORP Quinazoline derivatives as VEGF inhibitors
Feb, 2022

(2 years ago)

US8067427 GENZYME CORP Pharmaceutical compositions comprising ZD6474
Aug, 2028

(4 years from now)

Drugs and Companies using VANDETANIB ingredient

Market Authorisation Date: 06 April, 2011

Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease

Dosage: TABLET;ORAL

More Information on Dosage

CAPRELSA family patents

Family Patents

2. Cerdelga patents expiration

CERDELGA's oppositions filed in EPO
CERDELGA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6916802 GENZYME CORP Amino ceramide-like compounds and therapeutic methods of use
Apr, 2022

(1 year, 10 months ago)

US7196205 GENZYME CORP Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Jun, 2026

(2 years from now)

US11458119 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Nov, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615573 GENZYME CORP Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Apr, 2022

(1 year, 10 months ago)

US7253185 GENZYME CORP Amino ceramide-like compounds and therapeutic methods of use
Apr, 2022

(1 year, 10 months ago)

US10888547 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Jan, 2031

(6 years from now)

US10888544 GENZYME CORP Methods for treating Gaucher disease
Dec, 2038

(14 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: Treatment of gaucher disease type 1; Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat ...

Dosage: CAPSULE;ORAL

How can I launch a generic of CERDELGA before it's drug patent expiration?
More Information on Dosage

CERDELGA family patents

Family Patents